Abstract
We examined 59 breast cancers for p53 and bcl-2 protein expression by immunohistochemistry. The results were correlated with Ki-67 immunostaining. p53-negativity was noted in 40 cases and the remaining 19 tumours were p53-positive. Thirty-six tumours showed strong expression of bcl-2 and in 23 no staining for this protein was observed. We found statistically significant reverse correlation between expression of p53 and bcl-2 in majority of carcinomas: 31 cases were bcl-2 positive and p53-negative, and 14 tumours were bcl-2-negative and p53-positive. Six carcinomas showed no nuclear staining for Ki-67 and in the remaining 53 the percent of cancer cells positive for Ki-67 ranged from 1 to 60 (mean: 14.6). In these 53 cases we found that bcl-2-positive tumours were characterized by lower proliferation than bcl-2-negative tumours, the mean value of Ki-67 immunostaining being 10.7% and 23.0%, respectively. p53-negative tumours showed lower proliferation than p53-positive tumours: mean Ki-67 index was 10.2% and 23.9%, respectively.
We conclude that immunohistochemically detected p53 and bcl-2 proteins show a significant inverse relationship in majority of breast carcinomas and their expression correlates with tumour proliferation (Ki-67 immunostaining).
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Allred DC, Clark GM, Elledge R, Fuqua SAW, Brown RW, Chamnes GC, Osborne CK, McGuire WL (1993) Association of p53 protein expression with tumour cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst 85:200–206
Bursch W, Oberhammer F, Schulte-Herman G (1992) Cell death by apoptosis and its protective role against disease. TiPS 13:245–251
Cattoretti G, Rilke F, Andreola S, D'Amato L, Delia D (1988) p53 expression in breast cancer. Int J Cancer 41:178–183
Domagala W, Harezga B, Szadowska A, Markiewski M, Weber K, Osborn M (1993) Nuclear p53 protein accumulates preferentially in medullary and high-grade ductal but rarely in lobular breast carcinomas. Am J Pathol 142:669–674
Green DR, Cotter TG (1992) Introduction: apoptosis in the immune system. Semin Immunol 4:355–362
Hockenbery DM, Nunez G, Miliman C, Schreiber RD, Kormeyer SJ (1990) Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 348:334–336
Hockenbery DM, Zutter M, Hickey W, Nahm M, Korsmeyer SJ (1991) BCL-2 protein is topographically restricted in tissues characterized by apoptotic cell death. Proc Natl Acad Sci USA 88:6961–6965
Korsmeyer SJ (1992) Bcl-2 initiates a new category of oncogenes: Regulators of cell death. Blood 80:879–886
Leoncini L, Del Vecchio MT, Megha T, Barbini P, Galieni P, Pileri S, Sabattini E, Gherlinzoni F, Tosi P, Kraft R, Cottier H (1993) Correlations between apoptotic and proliferative indices in malignant non-Hodgkin's lymphomas. Am J Pathol 142:755–763
McDonnell TJ, Troncoso P, Brisbay SM, Logothetis C, Chung LWK, Hsieh JT, Tu SM, Campbell ML (1992) Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 52:6940–6944
Ostrowski JL, Sawan A, Wright HC, Hennessy HC, Lennard TJW, Angus B, Horne CHW (1991) p53 expression in human breast cancer related to survival and prognostic factors: An immunohistochemical study. J Pathol 164:75–81
Pezzella F, Morrison H, Jones M, Gatter KC, Lane D, Harris AL, Mason DY (1993) Immunohistochemical detection of p53 and bcl-2 proteins in non-Hodgkin's lymphoma. Histopathology 22:39–44
Silvestrini R, Veneroni S, Daidone MG, Benini E, Boracchi P, Mezzetti M, Di Fronzo G, Rilke F, Veronesi U (1994) The bcl-2 protein: a prognostic indicator strongly related to p53 protein in lymph node negative breast cancer patients. J Natl Cancer Inst 86:499–504
Spandidos DA, Karaiossifidi H, Malliri A, Linardopoulos S, Vassilaros S, Tsikkinis A, Field JK (1992) Expression of ras rbl and p53 proteins in human breast cancer. Anticancer Res 12:81–90
Thor AD, Moore DH II, Edgerton SM, Kawasaki ES, Reihsaus E, Lynch HT, Marcus JN, Schwartz L, Chen LC, Mayall BH, Smith HS (1992) Accumulation of p53 tumour suppressor gene protein: An independent marker of prognosis in breast cancers. J Natl Cancer Inst 84:845–855
Trudel M, Mulligan L, Cavenee W, Margolese R, Cote J, Gariepy G (1992) Retinoblastoma and p53 gene product expression in breast carcinoma: Immunohistochemical analysis and clinicopathologic correlation. Hum Pathol 23:1388–1394
Vaux DL (1993) Toward an understanding of the molecular mechanisms of physiological cell death. Proc Natl Acad Sci USA 90:786–789
Wyllie AH, Arends MJ, Morris RG, Walker SW, Evan G (1992) The apoptosis endonuclease and its regulation. Semin Immunol 4:389–397
Yonish-Rouach E, Resnitzky D, Lotem J, Sachs L, Kimchi A, Oren M (1991) Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin 6. Nature 352:345–347
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Gorczyca, W., Markiewski, M., Kram, A. et al. Immunohistochemical analysis of bcl-2 and p53 expression in breast carcinomas: their correlation with Ki-67 growth fraction. Vichows Archiv A Pathol Anat 426, 229–233 (1995). https://doi.org/10.1007/BF00191359
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00191359